A Phase I Trial Of G3139 (BCL-2 Antisense, NSC 683428, IND 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumours.

Trial Profile

A Phase I Trial Of G3139 (BCL-2 Antisense, NSC 683428, IND 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2013

At a glance

  • Drugs Oblimersen (Primary) ; Cyclophosphamide; Dexrazoxane; Doxorubicin; Filgrastim
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 23 Nov 2006 Status change
    • 24 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top